TNFAIP8

Across TCGA pan-cancer cohorts, TNFAIP8 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TNFAIP8 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher TNFAIP8 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TNFAIP8 expression acts as an unfavorable survival marker, although some lineages such as LUSC and GBM show a favorable association.

PRAD, HNSC, and CHOL are the cancer types where TNFAIP8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
HNSC	DFS	Median	All	0.190	0.695	.020	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
LUSC	DFS	Median	All	1.000	0.369	.043	3	view →
GBM	DFS	Median	All	1.000	0.192	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TNFAIP8–PRAD (DFS)

Open the PRAD breakdown →